Canada approves leqembi as global alzheimer’s drug race heats up

With Health Canada’s decision, Leqembi (lecanemab) is now approved in 51 countries and regions, including Japan, the United States, the European Union, China, South Korea, Taiwan, and Saudi Arabia. Marketing applications are also under review in nine additional countries.

The Canadian authorization covers treatment of patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease who are noncarriers or heterozygotes of the ApoE4 allele and have confirmed amyloid pathology.